PFCS
CRBP icon

Pale Fire Capital SE’s Corbus Pharmaceuticals CRBP Stock Holding History

Pale Fire Capital SE’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$200K Buy
21,350
+2,700
+14% +$22.7K 0.02% 54
2025
Q4 		$152K Buy
+18,650
New +$230K 0.01% 57

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pale Fire Capital SE's CRBP Position: Q1 2026 in Review

Pale Fire Capital SE increased its Corbus Pharmaceuticals (CRBP) stake by 14% in Q1 2026, buying an estimated $22.7K and bringing the position to 21,350 shares worth $200K. The position accounts for 0.02% of the portfolio, ranked #54.

Pale Fire Capital SE first reported a position in CRBP in Q4 2025 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Pale Fire Capital SE held 21,350 shares of Corbus Pharmaceuticals worth $200K as of Q1 2026.
  • Pale Fire Capital SE bought 2,700 Corbus Pharmaceuticals shares in Q1 2026, an estimated $22.7K.
  • Corbus Pharmaceuticals made up 0.02% of Pale Fire Capital SE's portfolio in Q1 2026, its #54 holding.
  • Pale Fire Capital SE first reported a position in Corbus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Pale Fire Capital SE's 13F filing for Q1 2026, filed 14 May 2026.